Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.

Inclusion Criteria: * High-risk proliferative diabetic retinopathy (HR-PDR) eyes (as defined in section 2). * BCVA at baseline \> 20/320 (25 letters in the ETDRS Chart) in the study eye. * Clear ocular media and adequate pupillary dilatation to permit good quality fundus photography. * Intraocular pressure \< 21 mmHg. * Type I, or Type II diabetic subjects as defined by the WHO criteria of either gender, and aged ≥ 18 years. * Women must be using effective contraception, be post-menopausal for at least 12 months prior to trial entry, or surgically sterile. * Ability to provide written informed consent. * Ability to return for all trial visits. Exclusion Criteria: * Eyes with prior scatter (panretinal). * Focal/grid photocoagulation, within the previous 6 months. * Fibrovascular proliferation with retinal traction. * Other cause of retinal neovascularization (retinal vein occlusion, radiation retinopathy or others). * Atrophy/scarring/fibrosis/ hard exudates involving the center of the macula. * Subjects who have received YAG laser within the previous 6 months. * Peripheral retinal cryoablation, or laser retinopexy (for retinal tears only), * Significant media opacities, which might interfere with visual acuity, assessment of toxicity or fundus photography. * Subjects should not be entered if there is likelihood that they will require cataract surgery within the following 1 year. * Any intraocular surgery within 6 months before trial enrolment. * Previous vitrectomy. * HbA1…